Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category, whereas...
Genetic Lingo01:11

Genetic Lingo

Overview
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Archetypal Visual Field Analysis of Patients With Chronic Leber Hereditary Optic Neuropathy in Relation to Visual Recovery.

Investigative ophthalmology & visual science·2026
Same author

Sustained attention in dementia with Lewy bodies: a task-based fMRI study.

Frontiers in aging neuroscience·2026
Same author

Expanding the landscape of tRNA pathogenic variants in mitochondrial DNA.

Brain communications·2026
Same author

Characterization of Inferior Rectus Muscle Action in Normal Subjects Using Real-Time Magnetic Resonance Imaging of the Orbit.

Craniomaxillofacial trauma & reconstruction·2026
Same author

Diagnostic Criteria and Management of MELAS and Stroke-Like Episodes: Consensus-Based Statements.

European journal of neurology·2026
Same author

LEBER HEREDITARY OPTIC NEUROPATHY: A CASE REPORT OF CONCURRENT RARE MITOCHONDRIAL MUTATIONS AND ABCA4 NUCLEAR GENE MUTATION.

Retinal cases & brief reports·2026
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo
08:17

Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo

Published on: September 22, 2017

Leber's Hereditary Optic Neuropathy.

Alfredo A Sadun1, Chiara La Morgia, Valerio Carelli

  • 1Thornton Professor of Vision, Departments of Ophthalmology and NeuroSurgery, Doheny Eye Institute and Keck-USC School of Medicine, Los Angeles, CA, 90033, USA.

Current Treatment Options in Neurology
|November 11, 2010
PubMed
Summary
This summary is machine-generated.

Leber's hereditary optic neuropathy (LHON) is a blinding disease caused by mitochondrial DNA mutations. While no cure exists, idebenone shows promise in limiting neurodegeneration and improving vision in LHON patients.

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

Related Experiment Videos

Last Updated: Jun 6, 2026

Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo
08:17

Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo

Published on: September 22, 2017

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

Area of Science:

  • Ophthalmology
  • Genetics
  • Mitochondrial Biology

Background:

  • Leber's hereditary optic neuropathy (LHON) is a maternally inherited condition causing blindness.
  • Specific mitochondrial DNA mutations affecting respiratory complex I are linked to LHON, but are not sufficient to cause disease.
  • Pathogenesis involves reduced ATP synthesis and increased oxidative stress, leading to retinal ganglion cell apoptosis.

Purpose of the Study:

  • To review current understanding of LHON pathogenesis.
  • To explore potential therapeutic strategies for LHON.
  • To highlight the challenges in treating visual loss after optic atrophy occurs.

Main Methods:

  • Review of existing literature on LHON.
  • Analysis of pathogenic mechanisms including mitochondrial dysfunction and oxidative stress.
  • Evaluation of emerging therapeutic approaches.

Main Results:

  • No definitive therapy currently exists to prevent or reverse LHON-related optic neuropathy.
  • Recent trials suggest idebenone may limit neurodegeneration and improve visual acuity.
  • Other potential treatments under investigation include gene therapy, mitochondrial biogenesis enhancers, and anti-apoptotic drugs.

Conclusions:

  • LHON is a complex mitochondrial disorder with no proven cure.
  • Early intervention is crucial as treatments are less effective after optic atrophy.
  • Emerging therapies like idebenone offer hope for managing LHON and preserving vision.